Infinity Pharmaceuticals, Inc.: Revision history

20 August 2022

• curprev 03:3803:38, 20 August 2022 95.149.241.133 talk 1,156 bytes +11 No edit summary undo

13 August 2022

• curprev 03:3803:38, 13 August 2022 109.180.50.163 talk 1,145 bytes +15 No edit summary undo

29 July 2022

• curprev 17:1817:18, 29 July 2022 >Chris 1,130 bytes +1,130 Created page with "Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. T..."